New drug shows promise for rare ovarian cancer in early trial
Disease control
Completed
This phase 2 trial tested the drug nirogacestat in 53 people with recurrent ovarian granulosa cell tumors, a rare type of ovarian cancer. The goal was to see if the drug could shrink tumors or slow the disease. Participants took nirogacestat orally, and researchers measured how m…
Phase: PHASE2 • Sponsor: SpringWorks Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC